Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Climb Bio (CLYM) Long-Term Investments (2021 - 2026)

Climb Bio filings provide 5 years of Long-Term Investments readings, the most recent being $36.7 million for Q1 2026.

  • Quarterly Long-Term Investments fell 63.18% to $36.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $36.7 million through Mar 2026, down 63.18% year-over-year, with the annual reading at $59.6 million for FY2025, 3.31% down from the prior year.
  • Long-Term Investments hit $36.7 million in Q1 2026 for Climb Bio, down from $59.6 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $102.7 million in Q2 2025 and bottomed at $7.0 million in Q3 2022.
  • Average Long-Term Investments over 4 years is $51.8 million, with a median of $48.2 million recorded in 2025.
  • The largest annual shift saw Long-Term Investments plummeted 70.53% in 2022 before it soared 261.86% in 2025.
  • Climb Bio's Long-Term Investments stood at $7.0 million in 2022, then skyrocketed by 785.07% to $61.6 million in 2024, then decreased by 3.31% to $59.6 million in 2025, then crashed by 38.33% to $36.7 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Long-Term Investments are $36.7 million (Q1 2026), $59.6 million (Q4 2025), and $88.9 million (Q3 2025).